Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's dis… Read more
Telomir Pharmaceuticals, Inc. Common Stock (TELO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.133x
Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a cash flow conversion efficiency ratio of -0.133x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-927.26K) by net assets ($6.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Telomir Pharmaceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Telomir Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Delhi Television Limited
NSE:NDTV
|
1.199x |
|
Hiroca Holdings Ltd
TW:1338
|
0.037x |
|
LabGenomics Co. Ltd
KQ:084650
|
-0.034x |
|
Beijing JIAYU Door Window Curtain
SHE:300117
|
-0.023x |
|
TJ media Co. Ltd
KQ:032540
|
-0.037x |
|
Big Sunshine Co Ltd
TW:1475
|
0.049x |
|
DIVA Laboratories Ltd
TWO:4153
|
0.053x |
|
PT Wijaya Karya (Persero) Tbk
F:5AA
|
0.007x |
Annual Cash Flow Conversion Efficiency for Telomir Pharmaceuticals, Inc. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $643.04K | $-5.07 Million | -7.885x | -602.39% |
| 2023-09-30 | $3.44 Million | $-3.86 Million | -1.123x | -324.51% |
| 2022-09-30 | $-937.28K | $-468.66K | 0.500x | -65.19% |
| 2021-09-30 | $-83.13K | $-119.40K | 1.436x | -- |